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Background
National guidelines recommend the same approach for treating hypertensive men and women. It is not known, however, whether current US antihypertensive medication utilization patterns and the resulting degrees of blood pressure (BP) control are similar or different among hypertensive women and men.
Methods
The study was a cross-sectional, nationally representative survey of the noninstitutionalized civilian US population. Persons aged ≥18 years from the National Health and Nutrition Examination Survey (NHANES) 1999-2004 were classified as hypertensive based on a BP ≥140/90 mm Hg, currently taking antihypertensive medication, or having been diagnosed by a physician.
results
Among hypertensives, the prevalence of antihypertensive medication use was significantly higher among women than men (61.4% vs. 56.8%), especially among middle-aged persons (40-49 years, 53.1% vs. 42.7%) and among non-Hispanic blacks (65.5% vs. 54.6%). Also, treated women were more likely than men to use diuretics (31.6% vs. 22.3%) and angiotensin receptor blockers (11.3% vs. 8.7%). Among treated hypertensives, the proportion taking three or more antihypertensive drugs was lower among women than men, especially among older persons (60-69 years: 12.3% vs. 19.8%, 70-79 years: 18.6% vs. 21.2%, and ≥80 years: 18.8% vs. 22.8%). Only 44.8% of treated women achieved BP control vs. 51.1% of treated men.
Hypertension remains a major public health challenge in the United States. Approximately 72 million Americans are currently living with hypertension, and the estimated direct and indirect costs for hypertension in 2007 were $66.4 billion. 1 Effective drug therapies have been available for several decades and the substantial benefit of hypertension treatment on coronary heart disease and stroke has been demonstrated in numerous clinical trials. [2] [3] [4] [5] However, most populationbased studies indicate that a large proportion of hypertensive persons who are on drug therapy still have elevated blood pressure (BP), and a considerable proportion of hypertensive persons are not even treated with any antihypertensive drug. [6] [7] [8] [9] As the prevalence of hypertension has increased over the past decade, 10 it is important to understand current antihypertensive medication utilization patterns and to study their impact on BP control and hypertension-related clinical outcomes.
Historically, hypertension in women has received little attention compared to their male counterparts because men have a higher incidence of total cardiovascular end points at all ages. 11 Early clinical trials of treating mild-to-moderate hypertension were primarily conducted on a middle-aged male population, and most decisions regarding hypertensive treatment for women prior to the 1990's were based on data obtained from trials done predominately on male patients. Although some studies have shown that the treatment of hypertension among women conferred less benefit against cardiac events compared to antihypertensive treatment among men, [12] [13] [14] 15, 16 and the national guidelines recommend the same approach for treating hypertensive men and women.
Antihypertensive medication use in the hypertensive population significantly increased in the past 10 years. 17 However, direct comparison of the reduction of BP using hypertensive treatment between men and women with the same age, the same ethnicity, and the same coexisting medical conditions has not been performed. To understand gender-related differences in the treatment and control of hypertension, we used the National Health and Nutrition Examination Survey (NHANES) 1999-2004 data to estimate the prevalence of antihypertensive medication use among US adults with hypertension, to compare the utilization patterns between hypertensive men and women, and to access the impact of pharmacological treatment on BP control rates.
Methods
The NHANES 1999-2004 is a continuous cross-sectional survey based on a nationally representative sample of the civilian noninstitutionalized US population. 18 Survey participants received a detailed in-person home interview, followed by a physical examination including BP measurements at a mobile examination center. Informed consent was obtained from all participants, and the protocol was approved by the institutional review board of the National Center for Health Statistics.
During the home interview, participants were asked, "Have you taken or used any prescription medicines in the past month?" Respondents who answered affirmatively were further asked to report the name, duration, and main reason for each product used. An interviewer recorded the exact product name from the medication container label. If the container was unavailable, the participant verbally reported this information. Antihypertensive agents reported by participants in NHANES 1999-2004 were identified and categorized into the following therapeutic classes: (i) diuretics, (ii) β-blockers, (iii) calcium channel blockers, (iv) angiotensin-converting enzyme inhibitors, (v) angiotensin receptor blockers, and (vi) other antihypertensive agents (including α 1 -blockers, central α 2 -agonists, direct vasodilators, and other centrally acting drugs). A person who reported using more than one antihypertensive medication, either as a single-combination pill or as multiple drugs, was only counted once for the any antihypertensive medication use category, and once within each drug class category. Each antihypertensive medication that was reported was, however, used to compute the total number of antihypertensive medications used within the past month.
A history of physician-diagnosed diabetes, stroke, congestive heart failure, angina pectoris, heart attack, or coronary heart disease was also assessed by questionnaire. Serum creatinine 19 as well as urine albumin and creatinine 20 were measured according to standard methods. Serum creatinine values for NHANES 1999-2000 data were corrected according to the recommended standards. 19 Glomerular filtration rate was estimated using the Modification of Diet in Renal Disease equation. 21 Chronic kidney disease was defined as either an estimated glomerular filtration rate <60 ml/min per 1.73 m 2 or >200 mg albumin per gram urinary creatinine. 2 BP was measured with the participant in the sitting position after 5 min of rest by trained physicians at the mobile examination center following a standard protocol. Appropriate cuff sizes were used for participants based on measurement of mid-arm circumference. The average of up to three measurements was used. Hypertension was defined as a mean systolic BP ≥140 mm Hg, a mean diastolic BP ≥90 mm Hg, currently taking antihypertensive medication, or being told at least twice by a physician or other health professional that one has high BP. 1, 10 Hypertensive subjects who reported taking any antihypertensive agent identified from the NHANES prescription medication data were considered as treated hypertensives. The NHANES 1999-2004 response rate for completion of the interview and health examination was 75%. 18 Of those, 5,510 adults aged ≥18 years were identified as hypertensives, 100 subjects were excluded due to lack of prescription medication data (n = 54) or pregnancy (n = 46). The final analytic sample was 5,410.
Statistical analyses were conducted using SAS (SAS Institute, Cary, NC) and SUDAAN (RTI, Research Triangle Park, NC). 22 Sample weights were used to account for differential probabilities of selection and the complex sample design and to obtain estimates representative of the noninstitutionalized US population aged ≥18 years. 18 Variance estimates were computed using the Taylor series linearization approximation approach. 23 An estimate with a relative s.e. ≥30% was considered statistically unreliable and noted in the tables. Statistical hypotheses were tested with a t-statistic or a χ 2 , as appropriate. Trend tests were used to evaluate changes in estimates across age groups. We also conducted logistic regression analysis to estimate prevalence of antihypertensive drug use and BP control rates according to gender, adjusted for age, race/ethnicity, and comorbidities using predictive marginal probabilities. 24 
results
Demographic and clinical characteristics of the hypertensive population by gender are summarized in Table 1 . The average age of women was >5.4 years than men. Compared to hypertensive men, hypertensive women were more likely to be non-Hispanic black, to have a higher systolic BP (143 mm Hg vs. 138 mm Hg, P < 0.001), a lower diastolic BP (74 mm Hg vs. 79 mm Hg, P < 0.001), and a higher pulse pressure (68 mm Hg vs. 59 mm Hg, P < 0.001). A higher percent of women had more severe hypertension (BP ≥160/100 mm Hg; women 22.5% vs. men 12.5%, P < 0.001). Women also had greater prevalences of obesity, chronic kidney disease or stroke. Men, however, were more likely to be smokers and to have ischemic heart disease including angina pectoris, coronary heart disease, and/or heart attack.
The unadjusted and multivariable adjusted proportions of hypertensive men and women receiving antihypertensive drugs are shown in Table 2 . The proportions using antihypertensive articles Hypertension Treatment and Control medication increased with age in both genders (P < 0.001). Mexican American persons were less likely to use antihypertensive medications compared to non-Hispanic white and black persons in both genders (P < 0.05). Women more frequently reported using antihypertensive medications compared to men overall, both among all race/ethnicity groups and among persons 40-59 years. Gender difference in antihypertensive drug use persisted even after adjusted for age, race/ethnicity and comorbidities, specifically among 40-49 years age group and non-Hispanic black persons. However, women with a prior history of stroke were less likely to receive drug therapy compared with their male counterparts. Among treated hypertensive persons, ~30% used two antihypertensive drugs, and <20% used three or more antihypertensive drugs ( Table 2) . Treated men and women had similar proportions for the use of two antihypertensive drugs across all age and race/ethnicity subgroups. However, women with kidney disease or ischemic heart disease were more likely than their male counterparts to receive 2 antihypertensive drugs. The proportion of use of three or more antihypertensive drugs was significantly lower among old women than old men. Table 3 compares the distribution of antihypertensive drug classes prescribed to hypertensive persons and to those with hypertensive complications. Both unadjusted and multivariable adjusted estimates indicated that nearly one-third of hypertensive women reported using diuretics in contrast to less than one-fourth of hypertensive men. Diuretic use was significantly higher among women than men for those with diabetes and kidney disease. Women were also more likely than men to use angiotensin receptor blockers, especially among those with diabetes. In contrast, angiotensinconverting enzyme inhibitor use was significantly lower among women than men for those with kidney disease. There were no gender differences in the use of β-blockers or calcium channel blockers.
Forty-five percent of treated women achieved BP control, whereas 51% of treated men achieved BP control ( Table 4) . Among both genders, the proportions of BP control rates decreased with age (P < 0.01) and non-Hispanic whites were more likely to have their BP controlled compared to nonHispanic blacks and Mexican Americans (P < 0.05). Gender differences in BP control rates were observed among older age groups. Multivariable adjusted analyses indicated that BP control rate was significantly lower among women than men, specifically for older persons, non-Hispanic whites, and those with coexisting medical conditions such as kidney disease, stroke, or ischemic heart disease. Poor systolic BP control was the major contribution to lower BP control rates observed in treated women.
Additional multivariable adjusted regression analyses were conducted to examine whether BP control rates differed among men and women treated with the same antihypertensive drug class. Among diuretic users, women were less likely than men to have their BP controlled (44.2% vs. 54.6%, P = 0.002). Among β-blocker users, women were also less likely than men to have their BP controlled (42.1% vs. 53.4%, P = 0.001). There were no gender differences in BP control rates among calcium channel blocker, angiotensin-converting enzyme inhibitor, or angiotensin receptor blockers users.
discussion
The findings of this study demonstrate that significant gender disparities continue to exist in hypertension treatment and control among the US hypertensive population. Consistent with previous reports, 7 women were more likely than men to use antihypertensive medications, but treated women were significantly less likely than men to achieve the recommended goals of therapy even after adjusting for differences in age, race/ethnicity, and comorbidities. When comparing men and women of the same age, ethnicity, or medical condition, gender differences for antihypertensive use were less apparent and appeared to be present only among the middle-aged group and non-Hispanic blacks. However, gender differences in the control of hypertension were most evident among older age groups, non-Hispanic whites, and those with a history of cardiovascular disease. Lower control rates among the elderly may partially contribute to the unfavorable outcomes seen in women. Although the Framingham Heart Study originally observed a consistently greater number of coronary heart disease events caused by hypertension in men compared with women at any age, other studies have estimated the attributable risk percent to be as great or greater in women. 25 As more women than men have hypertension, optimal BP control, particularly systolic BP control, may well result in a greater number of hypertension-related events prevented among women. To achieve therapeutic goals for hypertension treatment, national hypertension prescribing guidelines emphasize multidrug therapy and the use of a diuretic in the basic therapeutic regimen. 2 Our study found that less than one-third of the hypertensive population were being treated with a diuretic and less than half of treated persons had received more than one drug. Women appeared to be less aggressively treated, as evidenced by the lower use of three or more antihypertensive drugs, although their overall use of antihypertensive medication was higher compared to men. Owing to the crosssectional design of NHANES, we could not confirm whether the less aggressive therapy was associated with poorer BP control among currently treated women. However, large clinical trials have demonstrated that most patients with hypertension can achieve and sustain adequate BP control only with the use of multiple antihypertensive drugs. 26, 27 Utilization patterns for certain antihypertensive drug classes were also clearly different by gender. Women were more likely to use a diuretic compared to men. Seemingly, greater use of diuretics among women did not confer more benefit in terms of BP control. Instead, when examining individual drug classes, BP control rates were significantly lower among women than men treated with a diuretic or a β-blocker even after adjustment was made for differences in age, race/ethnicity, and coexisting medical conditions. This, however, contrasts with the results of long-term clinical trials of antihypertensive treatment, which have not demonstrated clinically significant gender differences in BP responses and outcomes. 15, 16 Fu and Levine 28 suggested that angiotensin-converting enzyme inhibitors plus dihydropyridine calcium channel blockers may be a particularly effective combination in elderly women with systolic hypertension based on Lipsitz's study. 29 Gender differences in response to pharmacologic treatment of hypertension may be incompletely understood. Further research appears warranted to compare men and women of similar ages and medical conditions directly to determine the precise levels of reduction of cardiovascular outcomes with hypertension treatment and control.
Hypertension, although typically asymptomatic, is a major risk factor for stroke, heart failure, and coronary heart disease. Hypertension is also commonly associated with diabetes and renal insufficiency. New clinical trials continue to demonstrate different clinical outcomes of therapies tailored to specific coexisting medical conditions. National guidelines have incorporated these findings and recommended preferred drug classes for treating hypertensive patients with different diseases, specifically with diabetes, chronic kidney disease, congestive heart failure, stroke, and ischemic heart disease. 2 Our study found that antihypertensive prescription patterns were generally compliant with current recommendations for both men and women with diabetes, heart failure, or ischemic heart disease.
BP control rates were poor among the US hypertensive population, especially among older women and those with coexisting medical conditions. The Department of Health and Human Services has established a national goal to control high BP in at least 70% of treated hypertensive patients by the year 2010. 30 Clinical trials, including the Antihypertensive 32 have shown that the relatively lower hypertension control rates that currently prevail in the general US hypertensive population can be substantially improved. The primary strength of this study is the use of current NHANES data with its nationally representative samples and oversampling of key demographic subgroups such as the elderly and racial/ethnic minorities. BP was measured by a physician using a standardized approach. Prescription medication data were collected by trained interviewers, with the use of an in-person, household interview protocol. Drug names were recorded and verified by inspection of medication containers. The observed gender differences in the prevalence of hypertension treatment and control in our study were based on an enhanced data collection protocol, incorporating BP questionnaire data, and prescription medication data. This allowed us to identify all antihypertensive agents currently used by hypertensive persons. Using the specific drug class data also allowed us to examine drug utilization patterns and outcomes more completely in terms of BP control as well as to illustrate how the national guidelines for antihypertensive therapy are currently being applied to the US hypertensive population.
However, several potential limitations of our study should be noted when interpreting our findings. First, while the auscultatory method of BP measurement in NHANES is fully consistent with national standards, NHANES measurements are performed only at a single time point, rather than on two separate occasions. It is therefore possible that some subjects were misclassified with regard to their BP control status. This potential problem was minimized to some extent by taking the average of three separate measurements obtained under the same standardized conditions. Second, NHANES is a cross-sectional study, and participants were asked to recall medications used in the past month to minimize recall bias. Thus, hypertensive subjects who used an antihypertensive drug at any time before the 1-month recall period are classified as nonusers. The prevalence estimates could be affected by the particular choice of a study recall period. In addition, drug dosage and strength information are not collected in NHANES. This limited our ability to address differences in drug therapy responses across demographic subgroups and clinical conditions. Third, antihypertensive medications may be used for other indications. In our data, 91% of antihypertensive users provided an affirmative answer to the question "current taking prescribed medicine for hypertension". The remaining 9% of antihypertensive users may have used the drug for another indication.
The treatment of hypertension and the assurance of BP control have been challenging and remain to some extent unsatisfactory. Potential benefits of antihypertensive therapy depend on both the efficacy of treatment and the underlying risks for cardiovascular disease in the individual subject. Although it is well demonstrated that age, race/ethnicity, and coexisting medical conditions are important considerations in BP control, gender is also a significant factor that needs to be considered. The gender disparities in hypertension treatment and control as evidenced by the current US national data will likely stimulate further prospective studies on whether the response to antihypertensive treatment is the same or different between the sexes. Ultimately, it is possible that men and women may require different antihypertensive regimens due to differences in the progression and presentation of hypertension. Efforts are still needed to achieve therapeutic goals for the US hypertensive population, especially for hypertensive women.
